Last updated on November 2019

A Study of DARZALEX (Daratumumab) In Indian Participants With Relapsed and Refractory Multiple Myeloma Whose Prior Therapy Included a Proteasome Inhibitor and an Immunomodulatory Agent


Brief description of study

The purpose of this study is to demonstrate the safety profile of daratumumab in routine clinical practice when given as monotherapy in Indian participants with relapsed and refractory multiple myeloma, whose prior therapy included a proteasome inhibitor and an immunomodulatory agent.

Clinical Study Identifier: NCT03768960

Find a site near you

Start Over